Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling
Neuropharmacology August 17, 2022 Jack E Henningfield, Marion A Coe, Roland R. Griffiths et al. 34 citations
New medicines containing classic hallucinogenic and entactogenic psychedelic substance are under development for various psychiatric and neurological disorders. Many of these, including psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) are Schedule I controlled substances of the United States Controlled Substances Act (US CSA), and similarly controlled...